17 June 2019 – GE Ventures to Sell its Portfolio

A fascinating feature for you courtesy of Tony Askew, co-founder and partner of REV Venture Partners, who spoke with Global Corporate Venturing about how the media industry has evolved since the corporate venturing unit was launched in 2000. Insights provided by Askew included how its co-investments with In-Q-Tel have helped the unit, while he also explained the group’s aim was to stay three to seven years ahead of everyone else.

Funds

WTW to broker corporate venturing deals

Third Rock counts $770m for fifth fund

Invengo invigorates $145m IoT fund

Crane crowns $90m close for first fund

Wavemaker drifts to $60m close for third fund

Exits

Salesforce processes $15.7bn Tableau acquisition

CrowdStrike is going public today after pricing a $612m IPO that represents a huge jump up from less than two weeks ago, when it was slated to float in an offering that would have raised $378m at its mid-point.

Merck & Co has agreed to acquire Tilos Therapeutics, which is developing antibodies to treat cancer, fibrosis and autoimmune diseases, in a deal that could potentially reach $773m once milestone payments are factored in.

That isn’t the only heavy-duty M&A exit to be agreed in the last day or so. H&R Block isbuying accounting software producer Wave Financial for $405m in cash.

Avi networks its way to VMWare acquisition

Barefoot takes next step with Intel purchase

Cvent goes DoubleDutch in acquisition deal

Deals

Short-term accommodation booking platform Oyo has reportedly begun talks with new and existing investors over a $1bn round that would value it at $10bn.

SoftBank’s recently launched $5bn Innovation Fund that focuses on Latin America has entered discussions with Brazil-based digital bank Nubank to lead a funding round that could reach up to $1bn and value the company at $8bn to $10bn – up from a previous reported valuation of $4bn, achieved when the fintech developer collected $180m from Tencent in October 2018.

SoftBank works out $300m Gympass investment

ADC Therapeutics adjusts series E to $276m

South Korea-based Yanolja also operates a short-term hotel business, refitting venues such as love hotels for a millennial user base seeking good quality accommodation on a budget. It has raised $180m in a series D round at a valuation of more than $1bn, with travel booking platform Booking Holdings joining Singapore’s GIC to supply the cash.

Innoviz has boosted a series C round that includes Harel Insurance and Phoenix Insurance from $132m to $170m, the extra funding coming from undisclosed investors.

Symphony plays on with $165m

Shuidi ships in $145m

Thumbtack, the US-based local services listing platform, has collected $120m in series H funding from unnamed investors – reportedly at a flat valuation of $1.3bn.

ShareChat in talks for $100m funding round

Dishangtie parks $100m in series B round

Vectra collects $100m in series E round

Infarm harvests $100m series B round


“Funky Chunk” Kevin MacLeod (incompetech.com)
Licensed under Creative Commons: By Attribution 3.0

8 February 2016 – Munce retires, Jasper exit, Sesame Street, Pierre Fabre and more…

Big news – people moves

Claudia Fan Munce’s retirement as managing director of IBM’s Venture Capital Group, following other high-profile departures such as Nagraj Kashyap and Arvind Sodhani over the past year.

Tom Hockaday leaving Isis.

Exits

Jasper (Singtel and Temasek) after Gilt last month.

Rocket Internet has sold its food ordering sites in Europe, Mexia and Brazil to Just Eat, a London-based competitor, for $140 million.

IPOs

China-based, Merck & Co-backed immuno-oncology drug developer BeiGene floated on Nasdaq yesterday in a $158m IPO, the same day as genome editing company Editas Medicine.

Editas is also trading up, and it wouldn’t be a surprise to see several more IPOs before the end of February.

But doubt it’ll be UBER, despite Fred Wilson’s demands as a non-shareholder.

Fundraising

Sesame Street’s new fund

Pierre Fabre, the 2nd largest French independent pharmaceutical group, have launched Pierre Fabre Fund for Innovation.

Two weeks ago, GlaxoSmithKline and Johnson & Johnson were among the founders of the UK-based Apollo Therapeutics Fund, and they’ve teamed up again as limited partners in the $230m first fund closed by Medicxis Ventures, a life sciences-focused firm spun out of venture firm Index Ventures. GSK and Johnson & Johnson were previously LPs in Medicxis’ predecessor, the first life sciences fund raised by Index, in 2012.
Plus debuts slow, although Luma has two intel capital veterans.

Kuwait potentially throwing $100bn at its sovereign wealth fund.